Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2024

May 13, 2024

BUY
$72.35 - $88.99 $2.71 Million - $3.34 Million
37,500 New
37,500 $113 Million
Q1 2023

May 12, 2023

BUY
$25.42 - $33.52 $2.54 Million - $3.35 Million
100,000 Added 45.5%
319,800 $48,000
Q4 2022

Feb 14, 2023

BUY
$18.46 - $36.37 $4.06 Million - $7.99 Million
219,800 New
219,800 $791,000

Others Institutions Holding NUVL

About Nuvalent, Inc.


  • Ticker NUVL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,977,800
  • Market Cap $4.02B
  • Description
  • Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...
More about NUVL
Track This Portfolio

Track Hap Trading, LLC Portfolio

Follow Hap Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Hap Trading, LLC with notifications on news.